IP Library › Granted Patent US 9,290,793
Granted Patent B2
US 9,290,793 · App. 14/210,058 · Granted Mar 22, 2016

Method of analyzing the charge profile of heparan N-sulfatase

Inventor: Daniel Roseman (Framingham, MA)
Assignee: Shire Human Genetic Therapies, Inc.
C12Q1/44C12N9/16C12Q3/00G01N33/6803
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,290,793
App. No.
14/210,058
Granted
Mar 22, 2016
Kind
B2
Abstract

The present invention provides, among other things, methods for the characterization of recombinant Heparan N-Sulfatase (HNS) during manufacture. The present invention uses capillary zone electrophoresis to determine the charge profile, isoform distribution, and/or glycan profile of recombinant HNS; and represents a quality feature for the batch consistency, storage stability, biological half-life, pharmacokinetic, pharmacodynamic and biological activity of the enzyme. In particular, such characterization methods may be beneficial to optimize conditions and ensure consistency for the manufacture of HNS for the treatment of a patient diagnosed with Sanfilippo syndrome using enzyme replacement therapy.

Claims (13)

1. A method of analyzing a charge profile of a heparan N-sulfatase (HNS) protein comprising characterizing the charge profile of the HNS protein by capillary zone electrophoresis (CZE),

wherein the CZE separates peak groups indicative of absence or presence of charge variants and,

wherein the charge variants are associated with absence or presence of varying amounts of sialic acid and/or mannose-6-phosphate.

2. The method of claim 1 , wherein the charge profile comprises at least 14 peak groups.

3. The method of claim 1 , wherein the characterizing comprises quantitatively determining relative migration time and/or relative peak area of each peak group.

4. The method of claim 1 , wherein the HNS protein is produced by mammalian cells.

5. The method of claim 1 , wherein the HNS protein is produced at a large scale.

6. The method of claim 1 , wherein the method comprises determining if there is variation in the charge profile of the HNS protein as compared to a reference.

7. The method of claim 1 , wherein the capillary zone electrophoresis is conducted under conditions such that longer migration times correspond to species of increasing negative charges.

8. The method of claim 1 , wherein the capillary zone electrophoresis is conducted using a buffer system comprising Tris.

9. The method of claim 8 , wherein the buffer system has a pH ranging from approximately 7.8-8.2.

10. The method of claim 1 , wherein the capillary zone electrophoresis is conducted using a capillary with a length ranging between 56-112.5 cm.

11. The method of claim 1 , wherein the charge profile comprises at least 5 peak groups.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2022
From: SHIRE HUMAN GENETIC THERAPIES, INC.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 061447/0760 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2014
From: ROSEMAN, DANIEL S.
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 033487/0575 →
Continuity (2)
Provisional Application 61779767 · Mar 13, 2013
Related Publication 20140294800A1 · Oct 2, 2014